BiotechTube
Biomere

Biomere

Worcester, United States· Est.
biomere.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17M

Overview

Biomere is a specialized preclinical CRO focused on generating critical PK/PD and early toxicology data to de-risk drug development for biotech and pharmaceutical clients. Founded in 1996 and now part of the JOINN Laboratories global network, the company leverages extensive vivarium capacity, laboratory sciences, and scientific expertise to run hundreds of rodent and large animal studies annually. Its core value proposition is accelerating go/no-go decisions for clients through fast, reliable in vivo studies, supported by a high client retention rate and strategic partnerships to expand service offerings.

Drug DeliverySmall Molecules

Technology Platform

Integrated preclinical CRO service platform featuring extensive vivarium capacity for rodent and large animal models, multidisciplinary scientific expertise in study design, and in-house endpoint analysis labs (PK/bioanalysis, pathology). Enhanced through partnerships for flow cytometry (SauveBio) and histology (Splice Histology).

Funding History

2
Total raised:$17M
Series A$15M
Seed$2M

Opportunities

Growth is driven by the persistent outsourcing trend in biopharma R&D and the critical need for high-quality PK/PD data to de-risk drug programs.
Strategic partnerships with specialty labs (e.g., SauveBio, Splice Histology) allow Biomere to offer more comprehensive data packages, increasing its value proposition and capturing more revenue per client.
Its location in the Boston biotech hub provides access to a dense and innovative client base.

Risk Factors

The company operates in a highly competitive preclinical CRO market against both large global players and niche specialists.
Revenue is tied to the funding cycles of the biotech sector, making it vulnerable to macroeconomic downturns that reduce R&D spending.
Operational risks include maintaining complex animal facilities and adhering to strict regulatory and accreditation standards (AAALAC, USDA, DEA).

Competitive Landscape

Biomere competes in the fragmented preclinical CRO market. Key competitors range from large, full-service global CROs like Charles River Laboratories and Labcorp's preclinical segment to smaller, regionally-focused specialists. Biomere differentiates itself through a focused offering on non-GLP PK/PD and early tox, a personalized client approach, and its strategic East Coast location serving the Boston biotech cluster.

More companies in Digital Health & Biotech SaaS →More companies in United States →